Comparative study of various DOACs for atrial fibrillation after cardiac surgery(prospective observation research)

Comparative study of various DOACs for atrial fibrillation after cardiac surgery(prospective observation research) - Comparative study of various DOACs for atrial fibrillation after cardiac surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030851

Enrollment

100

Registered

2018-01-17

Start date

2014-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who underwent cardiac surgery

Interventions

Apixaban group(2.5mgX2/day or 5mgX2/day) Edoxaban group (30mgX1/day or 60mgX1/day) Riveroxaban group(10mgX1/day or 15mgX1/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: atrial fibrillation after cardiac surgery

Exclusion criteria

Exclusion criteria: valve replacement surgery Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
Bleeding event Ischemic cerebrovascular event	—

Secondary

Measure	Time frame
Renal dysfunction, Hemoglobin, pericardial effusion (UCG).	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026